Your browser doesn't support javascript.
loading
Recent clinical researches and technological development in TIL therapy.
Matsueda, Satoko; Chen, Lei; Li, Hongmei; Yao, Hui; Yu, Fuli.
Afiliación
  • Matsueda S; Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA. satoko.matsueda@freshwindbiotech.com.
  • Chen L; Department of Neurosurgery, Tianjin Fifth Central Hospital, Tianjin, 300450, China.
  • Li H; Department of Oncology, Qingdao University Medical School, Qinddao, 266003, China.
  • Yao H; Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA.
  • Yu F; Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA.
Cancer Immunol Immunother ; 73(11): 232, 2024 Sep 12.
Article en En | MEDLINE | ID: mdl-39264449
ABSTRACT
Tumor-infiltrating lymphocyte (TIL) therapy represents a groundbreaking advancement in the solid cancer treatment, offering new hope to patients and their families with high response rates and long overall survival. TIL therapy involves extracting immune cells from a patient's tumor tissue, expanding them ex vivo, and infusing them back into the patient to target and eliminate cancer cells. This revolutionary approach harnesses the power of the immune system to combat cancers, ushering in a new era of T cell-based therapies along with CAR-T and TCR-therapies. In this comprehensive review, we aim to elucidate the remarkable potential of TIL therapy by delving into recent advancements in basic and clinical researches. We highlight on the evolving landscape of TIL therapy as a prominent immunotherapeutic strategy, its multifaceted applications, and the promising outcomes. Additionally, we explore the future horizons of TIL therapy, next-generation TILs, and combination therapy, to overcome the limitations and improve clinical efficacy of TIL therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfocitos Infiltrantes de Tumor / Neoplasias Límite: Animals / Humans Idioma: En Revista: Cancer Immunol Immunother / Cancer immunol. immunother / Cancer immunology and immunotherapy Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfocitos Infiltrantes de Tumor / Neoplasias Límite: Animals / Humans Idioma: En Revista: Cancer Immunol Immunother / Cancer immunol. immunother / Cancer immunology and immunotherapy Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos